Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Purple Biotech Ltd. - American Depositary Shares (PPBT)
Company Research
Source: GlobeNewswire
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024 REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CE
Show less
Read more
Impact Snapshot
Event Time:
PPBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PPBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PPBT alerts
High impacting Purple Biotech Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
PPBT
News
- Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
- Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswire
- Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
- Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswire
- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
PPBT
Analyst Actions
- 11/15/24 - HC Wainwright
PPBT
Sec Filings
- 12/6/24 - Form 6-K
- 12/5/24 - Form 6-K
- 12/4/24 - Form 6-K
- PPBT's page on the SEC website